http://jnci.oxfordjournals.org/content/89/7/497.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Portal Vein Chemotherapy for Colorectal Cancer: a Meta-analysis of 4000 Patients in 10 Studies </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/89/7/497" />
      <meta content="/jnci/89/7/497.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Portal Vein Chemotherapy for Colorectal Cancer: a Meta-analysis of 4000 Patients in 10 Studies"
            name="DC.Title" />
      <meta content="10.1093/jnci/89.7.497" name="DC.Identifier" />
      <meta content="1997-04-02" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta content="Portal Vein Chemotherapy for Colorectal Cancer: a Meta-analysis of 4000 Patients in 10 Studies"
            name="citation_title" />
      <meta content="04/02/1997" name="citation_date" />
      <meta content="89" name="citation_volume" />
      <meta content="7" name="citation_issue" />
      <meta content="497" name="citation_firstpage" />
      <meta content="505" name="citation_lastpage" />
      <meta content="89/7/497" name="citation_id" />
      <meta content="89/7/497" name="citation_id_from_sass_path" />
      <meta content="jnci;89/7/497" name="citation_mjid" />
      <meta content="10.1093/jnci/89.7.497" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/89/7/497.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/89/7/497.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/89/7/497.full.pdf"
            name="citation_pdf_url" />
      <meta content="http://jnci.oxfordjournals.org/content/89/7/497"
            name="citation_public_url" />
      <meta content="9086006" name="citation_pmid" />
      <meta name="citation_section" content="Article" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/89/7/488.short" rel="prev" />
      <link href="/content/89/7/506.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d28075913e1">var callbackToken='5370784B504068C';</script><script type="text/javascript" id="session-d28075913e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:15:02.045-07:00';
            var gSessionId = 'KgIVsrku2pj@pB@@gnFQeQ';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip';
            var gAuthnMethods2 = 'ip';
            var gAuthnIPs = '18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/89.7.497");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("19970402");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F89%2F7%2F497.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/89/7.toc">
                  <span xmlns="" class="volume-value">Volume 89</span>
                  <span xmlns="" class="issue-value"> Issue 7</span></a></li>
            <li>Pp. <span class="slug-pages">
                  497-505.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/89/7/497.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Portal Vein Chemotherapy for Colorectal Cancer: a Meta-analysis of 4000 Patients in 10 Studies</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="last" id="contrib-1"><span class="collab" id="collab-1">Liver Infusion Meta-analysis Group</span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address>
                           Imperial Cancer Research Fund/Medical Research Council Clinical Trial Service Unit, <span class="addr-line">Harkness Bldg., Radcliffe Infirmary, Oxford 0X2 6HE, U.K.</span>
                           
                        </address>
                     </li>
                     <li class="aff"><a id="aff-2" name="aff-2"></a><address>
                           Meta-analysis Group in Cancer Secretariat, Department of Oncology, Hôpital Henri Mondor, <span class="addr-line">51 av du Maréchal de Lattre de Tassigny, 9400 Créteil, France</span>
                           
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="corresp" id="corresp-1">
                        <em>*Correspondence and reprint requests to:</em> Liver Infusion Meta-analysis Group Secretariat, Imperial Cancer Research Fund/Medical Research Council Clinical Trial Service
                        Unit, Harkness Bldg., Radcliffe Infirmary, Oxford 0X2 6HE, U.K.; or Meta-analysis Group in Cancer Secretariat, Department
                        of Oncology, Hôpital Henri Mondor, 51 av du Maréchal de Lattre de Tassigny, 9400 Créteil, France.
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="1996-09-17"><span class="received-label">Received </span>September 17, 1996.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="1996-12-20"><span class="rev-recd-label">Revision received </span>December 20, 1996.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="1997-01-29"><span class="accepted-label">Accepted </span>January 29, 1997.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-1" title="Materials and Methods" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  
                  <p id="p-3">
                     <em>Background</em>: Systemic delivery of cytotoxic drugs yields relatively low doses in the liver, a major site of recurrence for colorectal
                     cancer. Giving chemotherapy by means of continuous portal vein infusion (PVI) into the liver during the immediate postoperative
                     period may improve therapeutic efficacy. <em>Purpose</em>: We undertook a meta-analysis to assess the effects on recurrence and survival of administering fluorouracil (5-FU)-based
                     chemotherapy by PVI after colorectal cancer surgery. <em>Methods</em>: Data on mortality and recurrence were sought for all patients enrolled in randomized trials initiated before 1987 in which
                     a few days (range, 5–7 days) of continuous postoperative PVI of cytotoxic drugs was compared with no further treatment. Data
                     from 10 trials (a promising initial study and nine hypothesis-testing trials) involving about 4000 patients were available
                     for analysis. The main cytotoxic drug in each trial was 5-FU (given with heparin); however, mitomycin C was co-administered
                     in two of the trials. Four trials included an additional control group of patients treated with continuous noncytotoxic PVI
                     of either heparin or urokinase alone; one trial included a second control group of patients treated with continuous systemic
                     infusion of 5-FU. Reported P values are two-sided. <em>Results</em>: Among the 3499 patients randomly assigned to receive either cytotoxic PVI or no further treatment, 1557 deaths are known
                     to have occurred. Survival with and without PVI appeared to be the same for the first 2 years; thereafter, it diverged significantly,
                     with the absolute survival difference (i.e., improvement) associated with PVI at 5 years being 4.7% (standard deviation [SD]
                     = 1.2%) (<em>P</em> = .006). When just the nine hypothesis-testing trials were considered, the absolute survival difference was 3.6% (SD = 1.2%)
                     (<em>P</em> = .04). If, ignoring any potential for bias in stage assignment, attention was restricted to patients with Dukes' stage A,
                     B, or C disease (88.3% of the total), the absolute effect on 5-year survival for all 10 trials increased to 6.0% (SD = 1.8%)
                     (<em>P</em> = .001); this estimate remained statistically significant when the initial study was excluded (absolute survival difference
                     = 4.8%; SD = 1.8%; <em>P</em> = .01). In contrast to the highly significant reduction in liver metastases seen in the initial study (79% reduction; SD
                     = 15%; <em>P</em> = .00000007), the reduction found in the nine hypothesis-testing trials was not significant (14% reduction; SD = 10%; <em>P</em> = .2). In the trials with additional control groups, survival appeared to be better with cytotoxic PVI than with noncytotoxic
                     PVI or with systemic cytotoxic drug infusion. Conclusions: PVI of 5-FU (with or without other cytotoxic drugs) for about 1
                     week after surgery in patients with colorectal cancer may produce an absolute improvement in 5-year survival of a few percent.
                     Although encouraging, this finding is not statistically secure, and additional evidence from randomized trials involving several
                     thousand more patients is needed.
                  </p>
                  
               </div>
               <p id="p-4">Colorectal cancer is one of the most common malignant diseases, with about half a million deaths and more than 700 000 new
                  cases diagnosed worldwide each year (<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1"><em>1</em></a>). Colorectal tumors can be resected in approximately three quarters of patients (<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2"><em>2</em></a>,<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3"><em>3</em></a>), but, even if there is apparently curative resection, up to half will subsequently develop an incurable recurrence. For
                  such a common disease, even treatments that are only moderately effective would be worth knowing about. For example, if a
                  widely practicable adjuvant treatment were shown reliably to change 50% into 55% long-term survival, its widespread use would
                  avoid many thousands of deaths each year. But, although improvements as small as 5% may be worthwhile, they are difficult
                  to detect without large-scale randomized evidence (<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4"><em>4</em></a>).
               </p>
               <p id="p-5">Systemic chemotherapy regimens involving fluorouracil (5FU) with or without other cytotoxic drugs appear, in general, to be
                  of limited effectiveness in preventing the recurrence of colorectal cancer (<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5"><em>5</em></a>,<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6"><em>6</em></a>). This finding may be a consequence of the fact that 5-FU is effective only against cancer cells that are undergoing DNA
                  synthesis. In addition, the majority of cancer cells will be unaffected by 5-FU bolus treatment, since the active metabolites
                  of this compound have half-lives of only about 10 minutes. Improved survival has been seen when 5-FU is combined with levamisole
                  (<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7"><em>7</em></a>)—an immunostimulant—but this result may be attributable to the large cumulative dose of 5-FU used in this regimen (<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8"><em>8</em></a>). Co-administration of folinic acid, a 5-FU biomodulator, considerably enhances the activity of 5-FU, and improved survival
                  is seen when this combination is used as an adjuvant treatment (<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9"><em>9</em></a>,<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10"><em>10</em></a>). Another consideration is that cytotoxic drugs administered systemically produce relatively low doses in the liver, which
                  is an important site of disease recurrence (<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11"><em>11</em></a>,<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12"><em>12</em></a>). Hence, a continuous infusion of cytotoxic drugs into the liver via the portal vein, for at least a few days during the
                  immediate postoperative period, has been proposed. Nonrandomized studies of portal vein infusion (PVI), using either thiotepa
                  (<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13"><em>13</em></a>) or mechlorethamine (<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14"><em>14</em></a>), were undertaken in the 1950s but were abandoned because of concerns about toxicity. The first randomized trial to test
                  cytotoxic PVI of 5-FU was initiated in 1975. Patients were randomly assigned to either surgery alone or to surgery plus a
                  1-week continuous infusion of 5-FU and heparin given via a catheter that had been inserted into a tributary of the portal
                  vein (<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15"><em>15</em></a>). The early results from this trial were highly encouraging (<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16"><em>16</em></a>), and, subsequently, at least 11 other randomized trials were begun between 1979 and 1984 (<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17"><em>17</em></a>–<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22"><em>22</em></a>). These studies were set up to detect large differences in survival similar to that reported in the original PVI study, so
                  no one study was large enough to detect a more moderate, but perhaps still worthwhile, improvement in 5-year survival (e.g.,
                  from 50% to 55%) (<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23"><em>23</em></a>).
               </p>
               <p id="p-6">A previous meta-analysis, based on just the published data, suggested a reduction of about one third in the risk of death
                  for patients allocated to liver infusion of 5-FU (<a id="xref-ref-6-2" class="xref-bibr" href="#ref-6"><em>6</em></a>). Reviews (<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24"><em>24</em></a>,<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25"><em>25</em></a>) of published results are, however, subject to various problems. In particular, some published reports exclude substantial
                  numbers of randomly assigned patients who were later deemed ineligible either because they were found at laparotomy to have
                  benign tumors or because they had clinically undetectable metastases or otherwise inoperable disease. Such patients allocated
                  to PVI did not usually receive it, and, even if they had, PVI would probably have been ineffective against advanced disease.
                  If such patients are included in an unbiased “intention-to-treat” comparison, they reduce the statistical power (<a id="xref-ref-23-2" class="xref-bibr" href="#ref-23"><em>23</em></a>); but, removing them might cause bias, especially if patients with unresectable disease are more likely to be excluded if
                  they are allocated to PVI than if they are not (e.g., because of more thorough investigations of the liver). If such “upstaging”
                  (or “stage migration”) did occur, then it would bias the stage-stratified results in favor of the PVI group because of the
                  “Will Rogers phenomenon” (<a id="xref-ref-26-1" class="xref-bibr" href="#ref-26"><em>26</em></a>). Those patients with stage A, B, or C disease who are reclassified to stage D because of special extra investigations are
                  likely to have a worse prognosis than the patients who remain as stage A, B, or C but a better prognosis than those who are
                  already classified as stage D. Paradoxically, therefore, such upstaging would not only improve the average prognosis of patients
                  classified as stage A to C but also would improve the prognosis of those classified as stage D. If no similar upstaging occurred
                  for the control subjects, an analysis of survival stratified by stage—or, similarly, an analysis omitting patients classified
                  as stage D—would be biased in favor of the PVI group. This bias can, however, be avoided by chiefly emphasizing the unstratified
                  intention-to-treat analysis of all patients allocated to PVI (irrespective of whether they were subsequently found perioperatively
                  to have unresectable disease) versus all allocated control subjects.
               </p>
               <p id="p-7">To help avoid these and other potential biases and to reduce random errors by having larger numbers to analyze (<a id="xref-ref-27-1" class="xref-bibr" href="#ref-27"><em>27</em></a>,<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28"><em>28</em></a>), a collaboration between PVI trialists was established to seek individual patient data from all randomly assigned patients
                  in all relevant trials. This report of that collaboration provides a more reliable assessment of the effect on survival and
                  on disease recurrence of intraportal 5-FU liver infusion immediately after tumor resection for colorectal cancer than is available
                  from any of the individual studies or from previous reviews.
               </p>
               <div class="section materials-methods" id="sec-1">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-2" title="Statistical Methods" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Materials and Methods</h2>
                  
                  <p id="p-8">All trials that included a randomization between a few days (range, 5–7 days) of continuous postoperative PVI of cytotoxic
                     chemotherapy versus no further treatment were eligible for the overview if the trial began before 1987 and if the method of
                     providing the randomization was one that should have precluded the possibility of prior knowledge of the treatment to be allocated.
                     The trials were sought through computer-based literature searches of the Medline, Cancerlit, and Excerpta Medica databases;
                     handsearching of selected cancer journals; hand-searching of abstract books from relevant cancer, oncology, and surgery meetings;
                     checking the citations in published reports of identified trials and review articles; searching of registers of trials; and
                     direct contact with trialists and other individuals.
                  </p>
                  
                  <p id="p-9">Twelve relevant trials were found, involving a total of about 4200 patients. Nine trials tested liver infusion of 5-FU with
                     heparin, one trial tested 5-fluorodeoxyuridine plus heparin, and two trials tested the combination of 5-FU, mitomycin C, and
                     heparin. Data are not available from one of the studies (<a id="xref-ref-29-1" class="xref-bibr" href="#ref-29"><em>29</em></a>), which involved only about 100 patients, or from a trial of 5-FU PVI versus intravenous 5-FU, which did not have an untreated
                     control arm and also involved only about 100 patients (<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30"><em>30</em></a>). Data are available for the other 10 trials (the promising initial study and nine “hypothesis-testing” trials), involving
                     about 4000 patients. The 5-FU was given as a continuous infusion through a tributary of the portal venous system, with the
                     most usual dose being 0.5 or 0.6 g/m<sup>2</sup> per day for 7 days. Two studies (<a id="xref-ref-15-2" class="xref-bibr" href="#ref-15"><em>15</em></a>,<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18"><em>18</em></a>) gave 5-FU at a fixed daily dose of1gtoall patients, which is equivalent to about 0.6 g/m2 for an average-sized patient,
                     and one study (<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19"><em>19</em></a>) used a higher dose of 5-FU (1 g/m<sup>2</sup> per day) for just 5 days. Heparin was given with the 5-FU to keep the catheters patent. It had been suggested that the anticoagulant
                     effects of heparin might have contributed to the benefit reported in the first study, perhaps by preventing the seeding of
                     micro-metastases released at surgery. Hence, three later studies (<a id="xref-ref-18-2" class="xref-bibr" href="#ref-18"><em>18</em></a>,<a id="xref-ref-19-2" class="xref-bibr" href="#ref-19"><em>19</em></a>) included a 7-day PVI of heparin alone as an additional control arm, and one (<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21"><em>21</em></a>) included an additional control arm in which patients received a 24-hour PVI of urokinase. Another proposed hypothesis for
                     PVI appearing to be so remarkably effective in the first study was that the timing (with treatment being given continuously
                     and immediately postoperatively) rather than the route of administration might be of importance, and so the Australasian study
                     included a third control arm with continuous 5-FU by peripheral intravenous infusion.
                  </p>
                  
                  <p id="p-10">Individual patient data were sought from the principal investigator for all patients ever randomly assigned in each trial
                     (including full details on those reclassified after randomization as having stage D disease or being otherwise “ineligible”).
                     The data items requested were the patient identifier, the date of surgery, the site and Dukes' stage (<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31"><em>31</em></a>) of the tumor, the sex and age of the patient, the date randomly assigned, the treatment allocated, the date and site of
                     first recurrence (i.e., whether or not the liver was involved), the date of death or date last contacted, and the cause of
                     death for patients who had died without any recorded recurrence. These data were checked centrally for internal consistency
                     and for consistency with any published results. Where appropriate, requests for clarification of the trial design and queries
                     about missing data or incomplete follow-up were sent back to the relevant trialist, and explanations were sought for any noteworthy
                     imbalances in patient characteristics between the treatment groups within a particular trial.
                  </p>
                  
               </div>
               <div class="section" id="sec-2">
                  <div class="section-nav"><a href="#sec-1" title="Materials and Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-3" title="Results" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Statistical Methods</h2>
                  
                  <p id="p-11">The methods used for the overview analyses and the format for the presentation of the results have been described elsewhere
                     (<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32"><em>32</em></a>,<a id="xref-ref-33-1" class="xref-bibr" href="#ref-33"><em>33</em></a>). Within each trial, the total number of events (e.g., liver recurrence, any recurrence, or death) observed (O) each year
                     among patients allocated to liver infusion was compared with the number that would be expected (E) on the basis of the average
                     outcome in the PVI and control groups. The difference will be negative if, in that year, the treated group fared better than
                     the control group. Its variance (V) is calculated by standard methods (<a id="xref-ref-32-2" class="xref-bibr" href="#ref-32"><em>32</em></a>). These annual statistics were summated (yielding the “logrank” O - E and its V) to help assess the effect of treatment in
                     that trial. The logrank statistics, one per trial, are then summed to provide an overall estimate of the effect of treatment.
                     All <em>P</em> values are two-sided.
                  </p>
                  
                  <p id="p-12">To describe the results of particular trials, or of an overview of several trials, odds ratios (ORs) can be calculated from
                     the logrank statistics. (An OR of 0.9 would correspond to an odds reduction of 10%.) For Dukes' stage A or B cancer, where
                     the background risk of death from the disease is only about one quarter, reductions of 10% or of 15% in the annual odds of
                     death would correspond to absolute reductions of only about 2% or 3%, respectively, in the absolute risk of death (i.e., 75%
                     survival would be increased to 77% or 78%). But, for stage C cancer, where about half of the patients will die of their disease,
                     reductions of 10% or of 15% in the annual odds of death would correspond to absolute reductions of about 4% or 6%, respectively,
                     in the absolute risk of death (i.e., 50% survival would be increased to 54% or 56%) (<a id="xref-ref-32-3" class="xref-bibr" href="#ref-32"><em>32</em></a>).
                  </p>
                  
                  <p id="p-13">Calculations for noncolorectal cancer deaths were censored at recurrence, and, because the causes of deaths occurring after
                     recurrence could not be ascertained reliably, the logrank statistics for colorectal cancer death were calculated by subtracting
                     the logrank statistics for noncolorectal cancer deaths from the log-rank statistics for all-cause mortality (<a id="xref-ref-33-2" class="xref-bibr" href="#ref-33"><em>33</em></a>). All randomly assigned patients are included in the main intention-to-treat analyses irrespective of eligibility. For the
                     subgroup comparisons in <a id="xref-fig-1-1" class="xref-fig" href="#F1">Table 1</a>, however, only the 3088 patients with stage A, B, or C disease are included to avoid potential confounding from differing
                     numbers of ineligible patients in different subgroups. This restriction avoids confounding in comparisons between subgroups,
                     but it might artificially inflate the apparent treatment benefit in all subgroups if selective stage migration has occurred
                     (<em>see</em> introduction to this article).
                  </p>
                  
               </div>
               <div class="section results" id="sec-3">
                  <div class="section-nav"><a href="#sec-2" title="Statistical Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-7" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Results</h2>
                  
                  <div id="sec-4" class="subsection">
                     
                     <h3>PVI Versus No Further Treatment</h3>
                     
                     <p id="p-14">
                        <strong>Survival.</strong> Of 3499 patients randomly assigned either to cytotoxic PVI or to no further treatment, 1557 (44.5%) are known to have died.
                        <a id="xref-fig-2-1" class="xref-fig" href="#F2">Fig. 1</a> shows the mortality results of the first hypothesis-generating trial and of the nine subsequent trials. The substantial mortality
                        reduction that was indicated by the first trial has not been seen in any of the subsequent trials. But, in eight of the nine,
                        the PVI group did have a somewhat lower risk of death, and the subtotal (b) for these nine studies indicates a reduction in
                        the annual odds of death of 11% (standard deviation [SD] 4 5%) that is itself of borderline conventional significance (<em>P</em> = .04). If all 10 trials are taken together, then the reduction in the annual odds of death becomes somewhat more significant
                        (13.6% [SD = 4.9%]; <em>P</em> = .006). But, in the hypothesis-generating study and in two of the other studies (Düsseldorf and Seattle), data on ineligible
                        patients could not be supplied for this overview; among the remaining seven studies, the mortality reduction is not quite
                        conventionally significant (10% [SD = 5%]; <em>P</em> = .07). Hence, the overview provides suggestive, but not definite, evidence that cytotoxic PVI can reduce the annual risk
                        of death by about 10% to 15%.
                     </p>
                     
                     <p id="p-15">
                        <a id="xref-fig-3-1" class="xref-fig" href="#F3">Fig. 2</a> shows the life table estimate for all randomly assigned patients in all 10 trials. This figure suggests that the survival
                        benefit does not appear until some years after treatment, eventually resulting in an absolute improvement in survival of 4.7%
                        (SD = 1.2%) (61.8% alive in the PVI group versus 57.1% in the control group, two-sided <em>P</em> = .006). However, with a survival benefit that is not highly statistically significant, this apparent late divergence of
                        the survival curves could be largely due to the play of chance. In the nine hypothesis-testing studies, the difference in
                        5-year survival was 3.6% (SD = 1.2%) (<em>P</em> = .04).
                     </p>
                     
                     <p id="p-16">
                        <strong>Survival by stage.</strong> The effect of PVI is subdivided in <a id="xref-fig-4-1" class="xref-fig" href="#F4">Fig. 3</a> according to the stage of disease. Of the 3499 patients studied, 3088 (88.3%) were classified as having stage A, B, or C
                        disease, while 7.7% (271 of 3499) were reclassified at laparotomy as having “advanced” disease, including incompletely resectable
                        locoregional disease as well as evidence of distant metastases. These patients with stage D disease are subdivided into two
                        groups according to whether or not metastases were discovered in the liver during surgery. One hundred eight patients (3.1%
                        of 3499) were found to have nonmalignant adenomas or, in a few cases, noncolorectal cancers, and the disease stage was unknown
                        for 0.9% (32 of 3499) of the patients. There were, however, relatively few deaths among individuals in these categories, so
                        their inclusion has little effect on the analyses.
                     </p>
                     
                     <p id="p-17">When the survival analyses are stratified for stage, the reduction in the odds of death with PVI increases from 13.6% in the
                        unstratified analyses of all 10 trials to 18.0%, and the <em>P</em> value becomes more extreme (changing from .006 to .0004). The changes stem partly from a slightly larger proportion of the
                        PVI group being classified as having stage D disease (8.2% versus 7.2%) and partly from survival among patients with stage
                        D disease in the PVI group being slightly better than survival among control patients (11% versus 6% alive). These differences
                        are what might be expected if, in a biased manner, patients with stage A to C disease were more likely to be “upstaged” to
                        stage D if they were allocated to the PVI group. But, contrary to the prior hypothesis, extra investigations of the liver
                        in the PVIgroup did not result in more liver metastases being discovered: 4.5% in PVI patients versus 4.8% in control patients.
                        Instead, the excess of patients with stage D disease was chiefly among those without overt liver involvement. In the three
                        studies from which information on ineligible patients was not available, the extent of such stage migration could not be investigated.
                     </p>
                     
                     <div id="F1" class="fig pos-anchor odd">
                        <div class="fig-inline"><img alt=" Table 1. " src="497/F1.medium.gif" /></div>
                        <div class="fig-caption"><span class="fig-label">
                              <strong>Table 1.</strong>
                              </span> 
                           
                           <p id="p-18" class="first-child">Reductions in the odds of death seen with cytotoxic portal vein infusion (PVI) compared with no further treatment (NFT) among
                              3088 patients with Dukes' stage A, B, or C disease, by stage, site, age, and sex*,†
                           </p>
                           
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     
                     <div id="F2" class="fig pos-anchor even">
                        <div class="fig-inline"><img alt=" Fig. 1. " src="497/F2.medium.gif" /></div>
                        <div class="fig-caption"><span class="fig-label">
                              <strong>Fig. 1.</strong>
                              </span> 
                           
                           <p id="p-19" class="first-child">Mortality by allocated treatment for all randomly assigned patients in 10 trials of portal vein infusion (PVI) of fluorouracil
                              (5-FU) with or without mitomycin C versus control with no infusion. The odds reduction for each trial is plotted as a black
                              square with a horizontal line indicating the 99% confidence (conf.) interval. The size of the square is proportional to the
                              variance (Var.), since this indicates the amount of statistical information provided by the trial. The overall odds reduction
                              is shown as a diamond, the width of which represents the 95% confidence interval for the overview. Cytotox. = cytotoxic; Obs.
                              = O = observed; Exp. = E 4expected; % &amp; SD = odds reduction and standard deviation; 2p = two-sided <em>P</em> value; UK = United Kingdom; NCCTG = North Central Cancer Treatment Group; CP = Cancer Project; FMit = 5-FU plus mitomycin
                              C; SAKK = Swiss Group for Clinical Cancer Research; CRAC I = Colorectal Adenocarcinoma Trial I; EORTC = European Organization
                              for Research and Treatment of Cancer; NSABP = National Surgical Adjuvant Breast and Bowel Project; and <em>x</em>
                              <sup>2</sup> = chi-squared. All <em>P</em> values are two-sided.
                           </p>
                           
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     
                     <p id="p-20">If only the patients with stage A, B, or C disease are analyzed (i.e., ignoring the possibility of bias being introduced into
                        the stage-specific analyses of some studies by stage migration), there is a more highly significant survival benefit for the
                        PVI group (odds reduction = 19% [SD = 5.3%]; = 4 .0004). The absolute effect on the 5-year survival for patients with stage
                        A, B, or C disease combined is 6.0% (SD = 1.8%]; <em>P</em> = .001) for all 10 trials, and it remains statistically significant if the hypothesis-generating trial is excluded (4.8%
                        [SD = 1.8%]; <em>P</em> = .01). The effects for patients with stage A/B and for patients with stage C disease in just the nine hypothesis-testing
                        studies are shown separately in <a id="xref-fig-5-1" class="xref-fig" href="#F5">Fig. 4</a>, although, as in <a id="xref-fig-4-2" class="xref-fig" href="#F4">Fig. 3</a>, it should be remembered that the apparent benefit of PVI in this stage-specific subgroup analysis will be exaggerated if
                        stage migration did occur. The apparent absolute benefits appear similar, at about 5%, for patients with stage A or B disease
                        as for patients with stage C disease.
                     </p>
                     
                     <p id="p-21">
                        <strong>Cause-specific mortality.</strong> Information was sought on the causes of death for patients who died without a recorded recurrence. Four hundred twenty such
                        deaths were identified, and the reported cause was available for 295 of them. Fifty-seven of these 295 deaths were “postoperative”
                        (defined for objectivity as any death occurring within 30 days of surgery), and they were about evenly divided between the
                        treatment groups: 32 (1.8%) among the 1759 patients allocated to the PVI group versus 25 (1.4%) among the 1740 patients allocated
                        to the control group. The deaths from known noncolorectal cancer causes were also evenly divided between the two treatment
                        groups: 151 (8.6%) allocated to the PVI group versus 144 (8.3%) allocated to the control group. For the remaining deaths,
                        however, most of which would have been due to colorectal cancer, there were significantly fewer in the PVI group than in the
                        control group (odds reduction = 17% [SD = 5%]; <em>P</em> = .002). The reduction was significantly larger in the first U.K. study (55% [SD = 14%]) than in the nine subsequent studies
                        (12% [SD = 6%]), but it was still conventionally significant (<em>P</em> = .04) in the latter.
                     </p>
                     
                     <p id="p-22">
                        <strong>Liver recurrence.</strong> Information on whether or not the liver was involved at first recurrence was provided from all trials: 36% (397 of 1111)
                        of first recurrences were known to involve the liver. There is highly significant (<em>P</em> = .0003) heterogeneity between the effects of PVI observed in the 10 studies (<a id="xref-fig-6-1" class="xref-fig" href="#F6">Fig. 5</a>). A striking result (seven versus 43 liver recurrences) is seen only in the first study, and there is a highly significant
                        (<em>P</em> = .000005) difference between this large reduction and the nonsignificant 14% (SD = 10%) reduction seen in the overview of
                        the nine subsequent trials (the results of which are not significantly inconsistent with each other).
                     </p>
                     
                  </div>
                  
                  <div id="sec-5" class="subsection">
                     
                     <h3>Additional Controls: PVI of Noncytotoxic Drugs and Peripheral Infusion of 5-FU</h3>
                     
                     <p id="p-23">Four of the 10 studies included a third arm of PVI with heparin alone or with urokinase. In <a id="xref-fig-7-1" class="xref-fig" href="#F7">Fig. 6</a>, a, the 417 patients in these additional control groups are compared with those receiving 5-FU plus heparin. Although no
                        individual study shows a statistically significant survival difference, when the four results are combined there were statistically
                        significantly fewer deaths (20% [SD = 10%] reduction; <em>P</em> = .04) with cytotoxic PVI than with noncytotoxic PVI. Three of these four studies used intraoperative randomization, and
                        the same surgical procedure was used in each treatment group, so selective re-staging of patients in one group seems much
                        less plausible. This conclusion is supported by a stage-stratified analysis that produces an identical 20% (SD = 10%) estimate
                        of treatment benefit, as does an analysis including just patients with stage A, B, or C disease. In these four comparisons,
                        there were also statistically significantly fewer liver recurrences among the 5-FU PVI patients (35% [SD = 17%] reduction;
                        <em>P</em> = .04) and fewer deaths from colorectal cancer (24% [SD = 12%]; <em>P</em> = .04). The Australasian study included a third arm in which patients received a continuous infusion of 5-FU given by peripheral
                        infusion instead of intraportally at the same dosage schedule, and there was a nonsignificant 14% (SD = 16%) reduction in
                        mortality with intraportal treatment (<a id="xref-fig-7-2" class="xref-fig" href="#F7">Fig. 6</a>, b).
                     </p>
                     
                     <div id="F3" class="fig pos-anchor odd">
                        <div class="fig-inline"><img alt=" Fig. 2. " src="497/F3.medium.gif" /></div>
                        <div class="fig-caption"><span class="fig-label">
                              <strong>Fig. 2.</strong>
                              </span> 
                           
                           <p id="p-24" class="first-child">Five-year survival for all 3499 patients in 10 studies of cytotoxic portal vein infusion. SD = standard deviation; 2p = two-sided
                              <em>P</em> value.
                           </p>
                           
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     
                     <div id="F4" class="fig pos-anchor even">
                        <div class="fig-inline"><img alt="Fig. 3." src="497/F4.medium.gif" /></div>
                        <div class="fig-caption"><span class="fig-label">Fig. 3.</span> 
                           
                           <p id="p-25" class="first-child">Mortality subtotals by disease stage in 10 trials of portal vein infusion (PVI) of fluorouracil with or without mitomycin
                              C versus control with no infusion. “Liver +ve” indicates patients with liver metastases who did not undergo curative surgery;
                              “liver -ve/uk” indicates other noncurative surgery; s.d. and SD = standard deviation. For a more complete explanation of symbols
                              and definitions of other abbreviations, see legend to <a id="xref-fig-2-2" class="xref-fig" href="#F2">Fig. 1</a>. <em>See</em> (<a id="xref-ref-31-2" class="xref-bibr" href="#ref-31"><em>31</em></a>) for information about Dukes' staging system.
                           </p>
                           
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     
                     <div id="F5" class="fig pos-anchor odd">
                        <div class="fig-inline"><img alt="Fig. 4." src="497/F5.medium.gif" /></div>
                        <div class="fig-caption"><span class="fig-label">Fig. 4.</span> 
                           
                           <p id="p-26" class="first-child">Five-year survival for the 2817 patients with stage A/B or C disease in nine hypothesis-testing studies of cytotoxic portal
                              vein infusion, subdivided by Dukes' stage and treatment allocation. SD = standard deviation; 2p = two-sided <em>P</em> value. <em>See</em> (<a id="xref-ref-31-3" class="xref-bibr" href="#ref-31"><em>31</em></a>) for information about Dukes' staging system.
                           </p>
                           
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     
                     <div id="F6" class="fig pos-anchor even">
                        <div class="fig-inline"><img alt="Fig. 5." src="497/F6.medium.gif" /></div>
                        <div class="fig-caption"><span class="fig-label">Fig. 5.</span> 
                           
                           <p id="p-27" class="first-child">Hepatic relapse as first event in 10 trials of portal vein infusion (PVI) of fluorouracil (5-FU) with or without mitomycin
                              C versus control with no infusion (patients with Dukes' stage A, B, or C disease only). For a more complete explanation of
                              symbols and definitions of abbreviations, <em>see</em> legend to <a id="xref-fig-2-3" class="xref-fig" href="#F2">Fig. 1</a>. All <em>P</em> values are two-sided.
                           </p>
                           
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     
                     <div id="F7" class="fig pos-anchor odd">
                        <div class="fig-inline"><img alt="Fig. 6." src="497/F7.medium.gif" /></div>
                        <div class="fig-caption"><span class="fig-label">Fig. 6.</span> 
                           
                           <p id="p-28" class="first-child">Fig. 6. Mortality by allocated treatment for all randomly assigned patients in five trials of intraportal cytotoxic infusion
                              versus intraportal noncytotoxic infusion or versus systemic cytotoxic infusion. Hep = heparin; UK (not bold) = urokinase.
                              For a more complete explanation of symbols and definitions of other abbreviations, <em>see</em> legend to <a id="xref-fig-2-4" class="xref-fig" href="#F2">Fig. 1</a>.
                           </p>
                           
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     
                  </div>
                  
                  <div id="sec-6" class="subsection">
                     
                     <h3>Effect of PVI in Different Subgroups of Patients</h3>
                     
                     <p id="p-29">The effects of 5-FU PVI on all-cause mortality and on deaths from colorectal cancer among the 3088 patients with stage A,
                        B, or C disease are shown in <a id="xref-fig-1-2" class="xref-fig" href="#F1">Table 1</a> for various subgroups. Overall, PVI was associated with an 18% (SD = 5%) reduction in the annual risk of death from any cause
                        and a 22% (SD = 6%) reduction in death from colorectal cancer. Each of these apparent treatment effects differs by only about
                        3 SD from zero, and so subgroup analyses may well yield untrustworthy results. Hence, the best estimate of the proportional
                        reduction in a particular subgroup may be that obtained indirectly, by extrapolation of the overall proportional reduction,
                        rather than that obtained directly from the effect actually observed in that subgroup (<a id="xref-ref-4-2" class="xref-bibr" href="#ref-4"><em>4</em></a>). For example, the best estimate of the proportional reduction in the annual risk of death among each of the groups of patients
                        with stage A, B, or C disease may well be the statistically more stable overall proportional risk reduction of 18% rather
                        than the less stable reductions of 27%, 18%, and 18%, respectively, that were actually seen in these subgroups. Likewise,
                        although the proportional reduction in the risk of death is highly significant in colon cancer (21% [SD = 6%]) but not in
                        rectal cancer (4% [SD = 11%]), it should not be concluded that PVI is effective for one but not the other. This caution is
                        given partly because a formal test of “interaction” (i.e., of whether there is a greater benefit from PVI among patients with
                        colon cancer than among patients with rectal cancer) is not statistically significant (<em>P</em> = .17), but chiefly because, if there is any real benefit from PVI, then the difference between its effect in different subgroups
                        is likely to be quantitative (i.e., a benefit in both subgroups, but a somewhat larger benefit for one) rather than qualitative
                        (i.e., a benefit for one subgroup but no benefit or harm for another) (<a id="xref-ref-4-3" class="xref-bibr" href="#ref-4"><em>4</em></a>). The other subgroup comparisons, which assess treatment among patients of different ages and sexes, provide no good evidence
                        even of quantitative interactions, with a statistically significant benefit seen even in the elderly patients (aged &gt;65 years).
                     </p>
                     
                  </div>
                  
               </div>
               <div class="section discussion" id="sec-7">
                  <div class="section-nav"><a href="#sec-3" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#notes-1" title="Notes" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Discussion</h2>
                  
                  <p id="p-30">These analyses suggest that a continuous infusion of 5-FU, administered postoperatively through the portal vein for about
                     1 week after surgery, may reduce the proportional risk of death over the next few years by about 10% or 15%, which might correspond
                     to an absolute 5-year survival improvement of about 5%. The four studies in which intraportal 5-FU was compared with intraportal
                     infusion of a noncytotoxic drug provide some further support for a real benefit of 5-FU by PVI. If the apparent survival benefit
                     from such a convenient procedure is real, then the finding would be important. Catheterization of a tributary of the portal
                     venous system is a relatively quick procedure that adds only about 10–15 minutes to the duration of colorectal cancer surgery,
                     5-FU is an inexpensive drug, usually no extra days of hospitalization are required, and major side effects are rare.
                  </p>
                  
                  <p id="p-31">However, although this overview brings together data from 3500 patients, the apparent survival benefit is not statistically
                     definite enough to form a basis for recommendations about whether the treatment should be adopted into routine use. This equivocal
                     conclusion stems partly from the fact that even a couple of thousand deaths are not enough to investigate reliably a 5% improvement
                     in 5-year survival and partly because there is no entirely satisfactory way of analyzing the randomly assigned patients who
                     had unresectable disease. Although there is no good evidence that the postrandomization classification of such patients was
                     appreciably biased (and, in particular, no evidence for the prior concern that liver metastases might have been more likely
                     to be identified at the time of surgery in the PVI arm), there are other ways in which bias could have been introduced (for
                     example, the definition of “inoperable” might, in some cases, have been related to difficulties in cannulation) on which adequate
                     data were not obtainable. So, the appropriate way of testing whether PVI of 5-FU really does influence survival is to analyze
                     all randomly assigned patients in an intention-to-treat analysis, even though this may weaken the statistical power to detect
                     a true survival difference. Ineligible patients also complicate description of the size of any benefits of PVI among eligible
                     patients. Because, if stage migration has occurred, then the estimate of the survival benefit just among patients with stage
                     A to C disease will be somewhat inflated. Conversely, intention-totreat analyses including patients with stage D disease,
                     who are likely to derive little or no benefit from PVI, will underestimate any real benefit for those with less advanced disease.
                     Future studies of cytotoxic PVI should, therefore, consider whether they can randomly assign patients intraoperatively to
                     minimize the number of ineligible patients assigned to trial treatments.
                  </p>
                  
                  <p id="p-32">Recently, it has been hypothesized that, if PVI of 5-FU is effective, it works chiefly because the drug is given perioperatively
                     and by continuous infusion and not because of the route of administration. This revised hypothesis originated with the finding
                     in the large study (<a id="xref-ref-22-2" class="xref-bibr" href="#ref-22"><em>22</em></a>) undertaken by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that, although recurrences as a whole were
                     significantly fewer in the PVI group, the apparent reduction was confined to nonliver metastases (with, indeed, slightly more
                     liver recurrences in the PVI group: 49 versus 46; <a id="xref-fig-6-2" class="xref-fig" href="#F6">Fig. 5</a>). However, seven of the other studies found fewer liver recurrences among patients receiving PVI, including the Rotterdam
                     study (<a id="xref-ref-21-2" class="xref-bibr" href="#ref-21"><em>21</em></a>), which found significantly fewer, and there is no significant difference between the effect in the NSABP study and the eight
                     other hypothesis-testing studies. Thus, although PVI of 5-FU does not appear to reduce liver metastases to the extent suggested
                     by the first study, the hypothesis-testing studies have not precluded a reduction of about one quarter in the risk of liver
                     metastases. Also, a reduction in the numbers of extrahepatic metastases does not necessarily imply that the same effect could
                     be achieved by giving 5-FU systemically. Dissemination to extrahepatic sites, such as lung and bone, can be the result of
                     secondary metastasis from the liver (<a id="xref-ref-34-1" class="xref-bibr" href="#ref-34"><em>34</em></a>). So, reducing micrometastases in the liver could have some effect on subsequent metastasis to other sites. The report (<a id="xref-ref-35-1" class="xref-bibr" href="#ref-35"><em>35</em></a>) that much higher levels of active 5-FU metabolites are found in the liver when 5-FU is given regionally than when it is
                     given systemically provides some support for the route of administration being important, but such theoretical arguments cannot
                     provide reliable answers as to the actual clinical risks and benefits of such treatment.
                  </p>
                  
                  <p id="p-33">Given the limited amount of data, it is difficult to compare the sizes of the benefits within different subgroups of trials
                     or patients. There is inadequate information, for example, to investigate whether the addition of mitomycin C in some studies
                     contributed to treatment efficacy. Furthermore, it is not known whether the apparently larger benefit among patients with
                     colon cancer, rather than rectal cancer, is real or whether it is largely or wholly due to chance. One observation to note,
                     though, is that colorectal cancer deaths are significantly reduced, even among patients who are more than 65 years of age.
                     The median age for colorectal cancer in developed countries is more than 70 years. So, a moderately effective and well-tolerated
                     treatment might be particularly useful for such patients.
                  </p>
                  
                  <p id="p-34">The present results are encouraging but not definitive. If ongoing trials of cytotoxic PVI succeed in recruiting several thousand
                     patients, then they will be able to define reliably the size of any survival benefit achievable with PVI. (The U.K. Adjuvant
                     X-ray and Infusion Study [AXIS] trial has randomly assigned 3000 patients out of an eventual target of 4000, and a Chinese
                     trial has randomly assigned intraoperatively 6000 patients out of an eventual target of at least 8000.) It may be that any
                     benefits of PVI are comparable in size with those of the newer, prolonged systemic chemotherapy regimens such as 5-FU/folinic
                     acid (<a id="xref-ref-9-2" class="xref-bibr" href="#ref-9"><em>9</em></a>,<a id="xref-ref-10-2" class="xref-bibr" href="#ref-10"><em>10</em></a>) or 5-FU/levamisole (<a id="xref-ref-7-2" class="xref-bibr" href="#ref-7"><em>7</em></a>)—in which case, the more convenient PVI might well be preferable—or it may be that greater benefit could be achieved by giving
                     both PVI and systemic chemotherapy. If a 1-week continuous infusion of about 1 g/day of 5-FU by PVI does reduce mortality
                     by 10%-15%, then it is likely that even greater benefit could be achieved by improving this regimen. For example, it could
                     be given for longer or at a higher dose, or it could be given in combination with 5-FU biomodulators or other drugs. These
                     and many other questions could be answered reliably by randomized trials that each involve several thousands of patients.
                     But, unless entry into randomized trials becomes a more routine part of hospital practice than it has been over the past few
                     decades, such trials are unlikely to be practicable.
                  </p>
                  
               </div>
               <div class="section notes" id="notes-1">
                  <div class="section-nav"><a href="#sec-7" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Notes</h2>
                  
                  <p id="p-35">The Secretariat and Writing Committee are as follows: R. Gray, M. Clarke, R. Collins, and R. Peto (Clinical Trial Service
                     Unit, Oxford, U.K.); P. Piedbois (Hôpital Henri Mondor, Paris, France); and M. Buyse (International Institute for Drug Development,
                     Brussels, Belgium).
                  </p>
                  
                  <p id="p-36">The trial groups and trialists that collaborated in the meta-analysis are, in alphabetical order of group, institute, or location,
                     as follows: B. Gray (Australasia); H. H. Gruenagel and M. Franzkowiak de Rodriguez (Düsseldorf, Evangelica Hospital); D. Nitti
                     and T. Sahmoud (European Organization for Research and Treatment of Cancer); L. P. Fielding, J. Fry, and R. Hittinger (Large
                     Bowel Cancer Project, U.K.); R. Beart, J. Ingle, M. Kahn, and M. O'Connell (North Central Cancer Treatment Group); H. Rockette
                     and N. Wolmark (National Surgical Adjuvant Breast and Bowel Project, United States); J. Wereldsma, E. D. M. Bruggink, W. S.
                     Meyer, J. A. Roukema, and W. van Putten (Rotterdam, The Netherlands); J. Crowley and J. Ryan (Virginia Mason Hospital, Seattle,
                     WA); U. Metzger, U. Laffer, M. Castiglione, and R. Maibach (Swiss Group for Clinical Cancer Research); and I. Taylor (UK First
                     Study).
                  </p>
                  
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#notes-1" title="Notes" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn-supported-by" id="fn-1">
                        
                        <p id="p-1">Supported by the Imperial Cancer Research Fund, the Ligue Nationale Française Contre le Cancer, the Conseil Général du Val
                           de Marne, and the BIOMED Programme of the European Community (grant PL 931247).
                        </p>
                        
                     </li>
                     <li class="fn-other" id="fn-2">
                        
                        <p id="p-2">We thank the thousands of patients who took part in these trials and so helped determine how best to treat colorectal cancer
                           and the medical, statistical, and administrative trial investigators who carefully checked any queries and provided details
                           on the trials. Vaughan Evans, Jon Godwin, Liz Greaves, and Gale Mead provided data processing, administrative, and secretarial
                           support.
                        </p>
                        
                     </li>
                  </ul>
               </div>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">(1)</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference (1) in text"
                           id="ref-1">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.1">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pisani</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Parkin</span>  <span class="cit-name-given-names">DM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ferlay</span>  <span class="cit-name-given-names">J</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future
                                    burden</span>. <abbr class="cit-jnl-abbrev">Int J Cancer</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">55</span>:<span class="cit-fpage">891</span>-<span class="cit-lpage">903</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8253525&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1993MM08900003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Estimates%20of%20the%20worldwide%20mortality%20from%20eighteen%20major%20cancers%20in%201985.%20Implications%20for%20prevention%20and%20projections%20of%20future%20burden&amp;author=P%20Pisani&amp;author=DM%20Parkin&amp;author=J%20Ferlay&amp;publication_year=1993&amp;journal=Int%20J%20Cancer&amp;volume=55&amp;pages=891-903">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(2)</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference (2) in text"
                           id="ref-2">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.2">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thomas</span>  <span class="cit-name-given-names">WH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Larson</span>  <span class="cit-name-given-names">RA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wright</span>  <span class="cit-name-given-names">HK</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cleveland</span>  <span class="cit-name-given-names">JC</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Analysis of 830 cases of rectal adenocarcinoma. 1. Progressively improved results of treatment</span>. <abbr class="cit-jnl-abbrev">Conn Med</abbr> <span class="cit-pub-date">1969</span>;<span class="cit-vol">33</span>:<span class="cit-fpage">569</span>-<span class="cit-lpage">70</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=5823555&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Analysis%20of%20830%20cases%20of%20rectal%20adenocarcinoma.%201.%20Progressively%20improved%20results%20of%20treatment&amp;author=WH%20Thomas&amp;author=RA%20Larson&amp;author=HK%20Wright&amp;author=JC%20Cleveland&amp;publication_year=1969&amp;journal=Conn%20Med&amp;volume=33&amp;pages=569-70">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(3)</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference (3) in text"
                           id="ref-3">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.3">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ohman</span>  <span class="cit-name-given-names">U</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Colorectal carcinoma. A survey of 1345 cases 1950–1984</span>. <abbr class="cit-jnl-abbrev">Acta Chir Scand</abbr> <span class="cit-pub-date">1985</span>;<span class="cit-vol">151</span>:<span class="cit-fpage">675</span>-<span class="cit-lpage">9</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=4096172&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1985AYD3800004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Colorectal%20carcinoma.%20A%20survey%20of%201345%20cases%201950%E2%80%931984&amp;author=U%20Ohman&amp;publication_year=1985&amp;journal=Acta%20Chir%20Scand&amp;volume=151&amp;pages=675-9">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(4)</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference (4) in text"
                           id="ref-4">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.4"
                             data-doi="10.1016/0895-4356(94)00150-O">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Peto</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Collins</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gray</span>  <span class="cit-name-given-names">R</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Large-scale randomized evidence: large simple, trials and overviews of trials</span>. <abbr class="cit-jnl-abbrev">J Clin Epidemiol</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">48</span>:<span class="cit-fpage">23</span>-<span class="cit-lpage">40</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0895-4356(94)00150-O&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7853045&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995QG57200006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Large-scale%20randomized%20evidence%3A%20large%20simple%2C%20trials%20and%20overviews%20of%20trials&amp;author=R%20Peto&amp;author=R%20Collins&amp;author=R%20Gray&amp;publication_year=1995&amp;journal=J%20Clin%20Epidemiol&amp;volume=48&amp;pages=23-40">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(5)</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference (5) in text"
                           id="ref-5">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.5"
                             data-doi="10.1001/jama.1988.03720240033031">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Buyse</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zeleniuch-Jacquotte</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chalmers</span>  <span class="cit-name-given-names">TC</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Adjuvant therapy of colorectal cancer. Why we still don't know</span>. <abbr class="cit-jnl-abbrev">JAMA</abbr> <span class="cit-pub-date">1988</span>;<span class="cit-vol">259</span>:<span class="cit-fpage">3571</span>-<span class="cit-lpage">8</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.1988.03720240033031&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3286920&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1988N776400025&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adjuvant%20therapy%20of%20colorectal%20cancer.%20Why%20we%20still%20don%27t%20know&amp;author=M%20Buyse&amp;author=A%20Zeleniuch-Jacquotte&amp;author=TC%20Chalmers&amp;publication_year=1988&amp;journal=JAMA&amp;volume=259&amp;pages=3571-8">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(6)</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference (6) in text"
                           id="ref-6">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.6">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gray</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">James</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mossman</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stenning</span>  <span class="cit-name-given-names">S</span></span></li>
                              </ol><cite>. <span class="cit-article-title">AXIS—a suitable case for treatment. UK Coordinating Committee on Cancer Research (UKCCCR) Colorectal Cancer Subcommittee</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">63</span>:<span class="cit-fpage">841</span>-<span class="cit-lpage">5</span>. <span class="cit-comment">[editorial]</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=2069842&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1991FU82300002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=AXIS%E2%80%94a%20suitable%20case%20for%20treatment.%20UK%20Coordinating%20Committee%20on%20Cancer%20Research%20%28UKCCCR%29%20Colorectal%20Cancer%20Subcommittee&amp;author=R%20Gray&amp;author=R%20James&amp;author=J%20Mossman&amp;author=S%20Stenning&amp;publication_year=1991&amp;journal=Br%20J%20Cancer&amp;volume=63&amp;pages=841-5">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(7)</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference (7) in text"
                           id="ref-7">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.7">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Moertel</span>  <span class="cit-name-given-names">CG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fleming</span>  <span class="cit-name-given-names">TR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Macdonald</span>  <span class="cit-name-given-names">JS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Haller</span>  <span class="cit-name-given-names">DG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Laurie</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tangen</span>  <span class="cit-name-given-names">CM</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report</span>. <abbr class="cit-jnl-abbrev">Ann Intern Med</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">122</span>:<span class="cit-fpage">321</span>-<span class="cit-lpage">6</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7847642&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995QJ08500001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Fluorouracil%20plus%20levamisole%20as%20effective%20adjuvant%20therapy%20after%20resection%20of%20stage%20III%20colon%20carcinoma%3A%20a%20final%20report&amp;author=CG%20Moertel&amp;author=TR%20Fleming&amp;author=JS%20Macdonald&amp;author=DG%20Haller&amp;author=JA%20Laurie&amp;author=CM%20Tangen&amp;publication_year=1995&amp;journal=Ann%20Intern%20Med&amp;volume=122&amp;pages=321-6">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(8)</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference (8) in text"
                           id="ref-8">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.8">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zalcberg</span>  <span class="cit-name-given-names">JR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Siderov</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Simes</span>  <span class="cit-name-given-names">J</span></span></li>
                              </ol><cite>; <span class="cit-auth cit-collab">on behalf of the Australasian Gastrointestinal Trials Group</span>. <span class="cit-article-title">The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">1996</span>;<span class="cit-vol">7</span>:<span class="cit-fpage">41</span>-<span class="cit-lpage">6</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=7/1/41"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(9)</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference (9) in text"
                           id="ref-9">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.9"
                             data-doi="10.1016/S0140-6736(95)90696-7">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators</span>. <span class="cit-article-title">Efficacy of adjuvant fluorouracil and folinic acid in colon cancer</span>. <abbr class="cit-jnl-abbrev">Lancet</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">345</span>:<span class="cit-fpage">939</span>-<span class="cit-lpage">44</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(95)90696-7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7715291&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995QT91900006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(10)</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference (10) in text"
                           id="ref-10">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.10">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wolmark</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rockette</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fisher</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wickerham</span>  <span class="cit-name-given-names">DL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Redmond</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fisher</span>  <span class="cit-name-given-names">ER</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from
                                    National Surgical Adjuvant Breast and Bowel Project Protocol C-03</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">11</span>:<span class="cit-fpage">1879</span>-<span class="cit-lpage">87</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=11/10/1879"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(11)</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference (11) in text"
                           id="ref-11">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.11">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cedarmark</span>  <span class="cit-name-given-names">BJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Blumenson</span>  <span class="cit-name-given-names">LE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pickren</span>  <span class="cit-name-given-names">JW</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Holyoke</span>  <span class="cit-name-given-names">DE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Elias</span>  <span class="cit-name-given-names">EG</span></span></li>
                              </ol><cite>. <span class="cit-article-title">The significance of metastases to the adrenal glands in adenocarcinoma of the colon and rectum</span>. <abbr class="cit-jnl-abbrev">Surg Gynecol Obstet</abbr> <span class="cit-pub-date">1977</span>;<span class="cit-vol">144</span>:<span class="cit-fpage">537</span>-<span class="cit-lpage">46</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=847609&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1977DA43000010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=The%20significance%20of%20metastases%20to%20the%20adrenal%20glands%20in%20adenocarcinoma%20of%20the%20colon%20and%20rectum&amp;author=BJ%20Cedarmark&amp;author=LE%20Blumenson&amp;author=JW%20Pickren&amp;author=DE%20Holyoke&amp;author=EG%20Elias&amp;publication_year=1977&amp;journal=Surg%20Gynecol%20Obstet&amp;volume=144&amp;pages=537-46">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(12)</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference (12) in text"
                           id="ref-12">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.12">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Goslin</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Steele</span>  <span class="cit-name-given-names">G</span>  <span class="cit-name-suffix">Jr</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zamcheck</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mayer</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">MacIntyre</span>  <span class="cit-name-given-names">I</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum</span>. <abbr class="cit-jnl-abbrev">Dis Colon Rectum</abbr> <span class="cit-pub-date">1982</span>;<span class="cit-vol">25</span>:<span class="cit-fpage">749</span>-<span class="cit-lpage">54</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7172942&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1982PU91300001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Factors%20influencing%20survival%20in%20patients%20with%20hepatic%20metastases%20from%20adenocarcinoma%20of%20the%20colon%20or%20rectum&amp;author=R%20Goslin&amp;author=G%20Steele&amp;author=N%20Zamcheck&amp;author=R%20Mayer&amp;author=I%20MacIntyre&amp;publication_year=1982&amp;journal=Dis%20Colon%20Rectum&amp;volume=25&amp;pages=749-54">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(13)</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference (13) in text"
                           id="ref-13">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.13">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Holden</span>  <span class="cit-name-given-names">WD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dixon</span>  <span class="cit-name-given-names">WJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A study on the use of triethylenethiophosporamide as an adjuvant to surgery in the treatment of colorectal cancer</span>. <abbr class="cit-jnl-abbrev">Cancer Chemother Rep</abbr> <span class="cit-pub-date">1962</span>;<span class="cit-vol">16</span>:<span class="cit-fpage">129</span>-<span class="cit-lpage">34</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=13908313&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20study%20on%20the%20use%20of%20triethylenethiophosporamide%20as%20an%20adjuvant%20to%20surgery%20in%20the%20treatment%20of%20colorectal%20cancer&amp;author=WD%20Holden&amp;author=WJ%20Dixon&amp;publication_year=1962&amp;journal=Cancer%20Chemother%20Rep&amp;volume=16&amp;pages=129-34">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(14)</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference (14) in text"
                           id="ref-14">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.14">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Morales</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bell</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">McDonald</span>  <span class="cit-name-given-names">GO</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cole</span>  <span class="cit-name-given-names">WH</span></span></li>
                              </ol><cite>. <span class="cit-article-title">The prophylactic treatment of cancer at the time of operation</span>. <abbr class="cit-jnl-abbrev">Ann Surg</abbr> <span class="cit-pub-date">1957</span>;<span class="cit-vol">146</span>:<span class="cit-fpage">588</span>-<span class="cit-lpage">95</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=13470750&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1957WF46600006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=The%20prophylactic%20treatment%20of%20cancer%20at%20the%20time%20of%20operation&amp;author=F%20Morales&amp;author=M%20Bell&amp;author=GO%20McDonald&amp;author=WH%20Cole&amp;publication_year=1957&amp;journal=Ann%20Surg&amp;volume=146&amp;pages=588-95">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(15)</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference (15) in text"
                           id="ref-15">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.15">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Taylor</span>  <span class="cit-name-given-names">I</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Machin</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mullee</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Trotter</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cooke</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">West</span>  <span class="cit-name-given-names">C</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer</span>. <abbr class="cit-jnl-abbrev">Br J Surg</abbr> <span class="cit-pub-date">1985</span>;<span class="cit-vol">72</span>:<span class="cit-fpage">359</span>-<span class="cit-lpage">63</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3888335&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1985AHW1900008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20randomized%20controlled%20trial%20of%20adjuvant%20portal%20vein%20cytotoxic%20perfusion%20in%20colorectal%20cancer&amp;author=I%20Taylor&amp;author=D%20Machin&amp;author=M%20Mullee&amp;author=G%20Trotter&amp;author=T%20Cooke&amp;author=C%20West&amp;publication_year=1985&amp;journal=Br%20J%20Surg&amp;volume=72&amp;pages=359-63">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(16)</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference (16) in text"
                           id="ref-16">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.16">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Taylor</span>  <span class="cit-name-given-names">I</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rowling</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">West</span>  <span class="cit-name-given-names">C</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Adjuvant cytotoxic liver perfusion for colorectal cancer</span>. <abbr class="cit-jnl-abbrev">Br J Surg</abbr> <span class="cit-pub-date">1979</span>;<span class="cit-vol">66</span>:<span class="cit-fpage">833</span>-<span class="cit-lpage">7</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=509055&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1979JA18700001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adjuvant%20cytotoxic%20liver%20perfusion%20for%20colorectal%20cancer&amp;author=I%20Taylor&amp;author=J%20Rowling&amp;author=C%20West&amp;publication_year=1979&amp;journal=Br%20J%20Surg&amp;volume=66&amp;pages=833-7">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(17)</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference (17) in text"
                           id="ref-17">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.17"
                             data-doi="10.1001/archsurg.1990.01410190095015">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Beart</span>  <span class="cit-name-given-names">RWJr</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Moertel</span>  <span class="cit-name-given-names">CG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wieand</span>  <span class="cit-name-given-names">HS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Leigh</span>  <span class="cit-name-given-names">JE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Windschitl</span>  <span class="cit-name-given-names">HE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">vanHeerden</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the
                                    Mayo Clinic and the North Central Cancer Treatment Group</span>. <abbr class="cit-jnl-abbrev">Arch Surg</abbr> <span class="cit-pub-date">1990</span>;<span class="cit-vol">125</span>:<span class="cit-fpage">897</span>-<span class="cit-lpage">901</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/archsurg.1990.01410190095015&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=2369315&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1990DM63400014&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adjuvant%20therapy%20for%20resectable%20colorectal%20carcinoma%20with%20fluorouracil%20administered%20by%20portal%20vein%20infusion.%20A%20study%20of%20the%20Mayo%20Clinic%20and%20the%20North%20Central%20Cancer%20Treatment%20Group&amp;author=RWJr%20Beart&amp;author=CG%20Moertel&amp;author=HS%20Wieand&amp;author=JE%20Leigh&amp;author=HE%20Windschitl&amp;author=JA%20vanHeerden&amp;publication_year=1990&amp;journal=Arch%20Surg&amp;volume=125&amp;pages=897-901">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(18)</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference (18) in text"
                           id="ref-18">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.18"
                             data-doi="10.1016/0140-6736(92)91708-G">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fielding</span>  <span class="cit-name-given-names">LP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hittinger</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Grace</span>  <span class="cit-name-given-names">RH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fry</span>  <span class="cit-name-given-names">JS</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Randomised controlled trial of adjuvant chemotherapy by portal-vein infusion after curative resection for colorectal adenocarcinoma</span>. <abbr class="cit-jnl-abbrev">Lancet</abbr> <span class="cit-pub-date">1992</span>;<span class="cit-vol">340</span>:<span class="cit-fpage">502</span>-<span class="cit-lpage">6</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0140-6736(92)91708-G&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=1354275&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1992JL23400002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Randomised%20controlled%20trial%20of%20adjuvant%20chemotherapy%20by%20portal-vein%20infusion%20after%20curative%20resection%20for%20colorectal%20adenocarcinoma&amp;author=LP%20Fielding&amp;author=R%20Hittinger&amp;author=RH%20Grace&amp;author=JS%20Fry&amp;publication_year=1992&amp;journal=Lancet&amp;volume=340&amp;pages=502-6">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(19)</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference (19) in text"
                           id="ref-19">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.19">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ryan</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Weiden</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Crowley</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bloch</span>  <span class="cit-name-given-names">K</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Adjuvant portal vein infusion for colorectal cancer: a 3-arm randomized trial</span>. <abbr class="cit-jnl-abbrev">Proc ASCO</abbr> <span class="cit-pub-date">1988</span>;<span class="cit-vol">7</span>:<span class="cit-fpage">95</span>. <span class="cit-comment">[abstract]</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adjuvant%20portal%20vein%20infusion%20for%20colorectal%20cancer%3A%20a%203-arm%20randomized%20trial&amp;author=J%20Ryan&amp;author=P%20Weiden&amp;author=J%20Crowley&amp;author=K%20Bloch&amp;publication_year=1988&amp;journal=Proc%20ASCO&amp;volume=7&amp;pages=95">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(20)</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-89.7.497.20">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">Swiss Group for Clinical Cancer Research (SAKK)</span>. <span class="cit-article-title">Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer</span>. <abbr class="cit-jnl-abbrev">Lancet</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">345</span>:<span class="cit-fpage">349</span>-<span class="cit-lpage">53</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7845115&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995QF72200008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(21)</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference (21) in text"
                           id="ref-21">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.21"
                             data-doi="10.1002/1097-0142(19900201)65:3&lt;425::AID-CNCR2820650309&gt;3.0.CO;2-M">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wereldsma</span>  <span class="cit-name-given-names">JC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bruggink</span>  <span class="cit-name-given-names">ED</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Meijer</span>  <span class="cit-name-given-names">WS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Roukema</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">van Putten</span>  <span class="cit-name-given-names">WL</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of
                                    a prospective randomized clinical trial (Colorectal Adenocarcinoma Trial I)</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1990</span>;<span class="cit-vol">65</span>:<span class="cit-fpage">425</span>-<span class="cit-lpage">32</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19900201)65:3%3C425::AID-CNCR2820650309%3E3.0.CO;2-M&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=2404556&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adjuvant%20portal%20liver%20infusion%20in%20colorectal%20cancer%20with%205-fluorouracil%2Fheparin%20versus%20urokinase%20versus%20control.%20Results%20of%20a%20prospective%20randomized%20clinical%20trial%20%28Colorectal%20Adenocarcinoma%20Trial%20I%29&amp;author=JC%20Wereldsma&amp;author=ED%20Bruggink&amp;author=WS%20Meijer&amp;author=JA%20Roukema&amp;author=WL%20van%20Putten&amp;publication_year=1990&amp;journal=Cancer&amp;volume=65&amp;pages=425-32">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(22)</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference (22) in text"
                           id="ref-22">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.22">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wolmark</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rockette</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wickerham</span>  <span class="cit-name-given-names">DL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fisher</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Redmond</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fisher</span>  <span class="cit-name-given-names">ER</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary
                                    results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1990</span>;<span class="cit-vol">8</span>:<span class="cit-fpage">1466</span>-<span class="cit-lpage">75</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=8/9/1466"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(23)</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference (23) in text"
                           id="ref-23">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.23">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Peto</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pike</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Armitage</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Breslow</span>  <span class="cit-name-given-names">NE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cox</span>  <span class="cit-name-given-names">DR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Howard</span>  <span class="cit-name-given-names">SV</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Design and analysis of randomised clinical trials requiring prolonged observation of each patient I: introduction and design</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">1976</span>;<span class="cit-vol">34</span>:<span class="cit-fpage">585</span>-<span class="cit-lpage">612</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=795448&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1976CQ95300002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Design%20and%20analysis%20of%20randomised%20clinical%20trials%20requiring%20prolonged%20observation%20of%20each%20patient%20I%3A%20introduction%20and%20design&amp;author=R%20Peto&amp;author=M%20Pike&amp;author=P%20Armitage&amp;author=NE%20Breslow&amp;author=DR%20Cox&amp;author=SV%20Howard&amp;publication_year=1976&amp;journal=Br%20J%20Cancer&amp;volume=34&amp;pages=585-612">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(24)</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference (24) in text"
                           id="ref-24">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.24">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Buyse</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Meta-analyses use and misuse</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">11</span>:<span class="cit-fpage">38</span>. <span class="cit-comment">[letter]</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Meta-analyses%20use%20and%20misuse&amp;author=M%20Buyse&amp;publication_year=1993&amp;journal=J%20Clin%20Oncol&amp;volume=11&amp;pages=38">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(25)</span><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference (25) in text"
                           id="ref-25">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.25">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Clarke</span>  <span class="cit-name-given-names">MJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stewart</span>  <span class="cit-name-given-names">LA</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Obtaining data from randomized controlled trials: how much do we need for reliable and informative meta-analyses?</span> <abbr class="cit-jnl-abbrev">BMJ</abbr> <span class="cit-pub-date">1994</span>;<span class="cit-vol">309</span>:<span class="cit-fpage">1007</span>-<span class="cit-lpage">10</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=309/6960/1007"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(26)</span><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference (26) in text"
                           id="ref-26">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.26">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Feinstein</span>  <span class="cit-name-given-names">AR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sosin</span>  <span class="cit-name-given-names">DM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wells</span>  <span class="cit-name-given-names">CK</span></span></li>
                              </ol><cite>. <span class="cit-article-title">The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival
                                    in cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr> <span class="cit-pub-date">1985</span>;<span class="cit-vol">312</span>:<span class="cit-fpage">1604</span>-<span class="cit-lpage">8</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=4000199&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1985AKG1600004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=The%20Will%20Rogers%20phenomenon.%20Stage%20migration%20and%20new%20diagnostic%20techniques%20as%20a%20source%20of%20misleading%20statistics%20for%20survival%20in%20cancer&amp;author=AR%20Feinstein&amp;author=DM%20Sosin&amp;author=CK%20Wells&amp;publication_year=1985&amp;journal=N%20Engl%20J%20Med&amp;volume=312&amp;pages=1604-8">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(27)</span><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference (27) in text"
                           id="ref-27">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.27">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Collins</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gray</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Godwin</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Peto</span>  <span class="cit-name-given-names">R</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic
                                    overviews</span>. <abbr class="cit-jnl-abbrev">Stat Med</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">6</span>:<span class="cit-fpage">245</span>-<span class="cit-lpage">54</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3616282&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1987H713900004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Avoidance%20of%20large%20biases%20and%20large%20random%20errors%20in%20the%20assessment%20of%20moderate%20treatment%20effects%3A%20the%20need%20for%20systematic%20overviews&amp;author=R%20Collins&amp;author=R%20Gray&amp;author=J%20Godwin&amp;author=R%20Peto&amp;publication_year=1987&amp;journal=Stat%20Med&amp;volume=6&amp;pages=245-54">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(28)</span><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference (28) in text"
                           id="ref-28">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.28"
                             data-doi="10.1016/0140-6736(93)93004-K">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stewart</span>  <span class="cit-name-given-names">LA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Parmar</span>  <span class="cit-name-given-names">MK</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Meta-analysis of the literature or of individual patient data: is there a difference?</span> <abbr class="cit-jnl-abbrev">Lancet</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">341</span>:<span class="cit-fpage">418</span>-<span class="cit-lpage">22</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0140-6736(93)93004-K&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8094183&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1993KM41600018&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Meta-analysis%20of%20the%20literature%20or%20of%20individual%20patient%20data%3A%20is%20there%20a%20difference%3F&amp;author=LA%20Stewart&amp;author=MK%20Parmar&amp;publication_year=1993&amp;journal=Lancet&amp;volume=341&amp;pages=418-22">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(29)</span><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference (29) in text"
                           id="ref-29">↵</a>
                        
                        
                        <div class="cit ref-cit ref-confproc" id="cit-89.7.497.29">
                           <div class="cit-metadata">
                              <ol class="cit-ed-list">
                                 <li><span class="cit-ed"><span class="cit-name-surname">Schlag</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-ed"><span class="cit-name-surname">Saeger</span>  <span class="cit-name-given-names">HD</span></span>, 
                                 </li>
                                 <li><span class="cit-ed"><span class="cit-name-surname">Friedl</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>, editors. <span class="cit-article-title">Perioperative adjuvant intraportal FUDR-chemotherapy does not influence prognosis of colon cancer patients</span>. <span class="cit-conf-name">In proceedings of the Sixth International Conference on the Adjuvant Therapy of Cancer</span>. <span class="cit-pub-date">1990</span>. <span class="cit-comment">[abstract]</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Perioperative%20adjuvant%20intraportal%20FUDR-chemotherapy%20does%20not%20influence%20prognosis%20of%20colon%20cancer%20patients&amp;author=P%20Schlag&amp;author=HD%20Saeger&amp;author=P%20Friedl&amp;publication_year=1990">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(30)</span><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference (30) in text"
                           id="ref-30">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.30"
                             data-doi="10.1007/BF00311529">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kimura</span>  <span class="cit-name-given-names">O</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kurayoshi</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hoshino</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sugezawa</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Makino</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kaibara</span>  <span class="cit-name-given-names">N</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal
                                    cancer</span>. <abbr class="cit-jnl-abbrev">Surg Today</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">25</span>:<span class="cit-fpage">211</span>-<span class="cit-lpage">6</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/BF00311529&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7640448&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995QX45900004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Prophylactic%20portal%20infusion%20chemotherapy%20as%20adjuvant%20therapy%20for%20the%20prevention%20of%20metachronous%20liver%20metastasis%20in%20colorectal%20cancer&amp;author=O%20Kimura&amp;author=K%20Kurayoshi&amp;author=K%20Hoshino&amp;author=A%20Sugezawa&amp;author=M%20Makino&amp;author=N%20Kaibara&amp;publication_year=1995&amp;journal=Surg%20Today&amp;volume=25&amp;pages=211-6">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(31)</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference (31) in text"
                           id="ref-31">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.31"
                             data-doi="10.1002/path.1700350303">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dukes</span>  <span class="cit-name-given-names">CE</span></span></li>
                              </ol><cite>. <span class="cit-article-title">The classification of cancer of the rectum</span>. <abbr class="cit-jnl-abbrev">J Pathol</abbr> <span class="cit-pub-date">1932</span>;<span class="cit-vol">35</span>:<span class="cit-fpage">323</span>-<span class="cit-lpage">32</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/path.1700350303&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=000188408900002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=The%20classification%20of%20cancer%20of%20the%20rectum&amp;author=CE%20Dukes&amp;publication_year=1932&amp;journal=J%20Pathol&amp;volume=35&amp;pages=323-32">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(32)</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference (32) in text"
                           id="ref-32">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.32">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">Early Breast Cancer Trialists' Collaborative Group</span>. <span class="cit-article-title">Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000
                                    recurrences and 24,000 deaths among 75,000 women</span>. <abbr class="cit-jnl-abbrev">Lancet</abbr> <span class="cit-pub-date">1992</span>;<span class="cit-vol">339</span>:<span class="cit-fpage">71</span>-<span class="cit-lpage">85</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=1345869&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1992GZ15600001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(33)</span><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference (33) in text"
                           id="ref-33">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.33"
                             data-doi="10.1056/NEJM199511303332202">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">Early Breast Cancer Trialists' Collaborative Group</span>. <span class="cit-article-title">Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">333</span>:<span class="cit-fpage">1444</span>-<span class="cit-lpage">55</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM199511303332202&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7477144&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995TG44500002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(34)</span><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference (34) in text"
                           id="ref-34">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.34"
                             data-doi="10.1002/path.1711500308">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Weiss</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Grundmann</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Torhorst</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hartveit</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Moberg</span>  <span class="cit-name-given-names">I</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Eder</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies</span>. <abbr class="cit-jnl-abbrev">J Pathol</abbr> <span class="cit-pub-date">1986</span>;<span class="cit-vol">150</span>:<span class="cit-fpage">195</span>-<span class="cit-lpage">203</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/path.1711500308&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3806280&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1986F211900007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Haematogenous%20metastatic%20patterns%20in%20colonic%20carcinoma%3A%20an%20analysis%20of%201541%20necropsies&amp;author=L%20Weiss&amp;author=E%20Grundmann&amp;author=J%20Torhorst&amp;author=F%20Hartveit&amp;author=I%20Moberg&amp;author=M%20Eder&amp;publication_year=1986&amp;journal=J%20Pathol&amp;volume=150&amp;pages=195-203">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(35)</span><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference (35) in text"
                           id="ref-35">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-89.7.497.35">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Goldberg</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kerr</span>  <span class="cit-name-given-names">DJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Willmott</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">McKillop</span>  <span class="cit-name-given-names">JH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">McArdle</span>  <span class="cit-name-given-names">CS</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">1988</span>;<span class="cit-vol">57</span>:<span class="cit-fpage">186</span>-<span class="cit-lpage">9</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3358909&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1988M779700013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Pharmacokinetics%20and%20pharmacodynamics%20of%20locoregional%205%20fluorouracil%20%285FU%29%20in%20advanced%20colorectal%20liver%20metastases&amp;author=JA%20Goldberg&amp;author=DJ%20Kerr&amp;author=N%20Willmott&amp;author=JH%20McKillop&amp;author=CS%20McArdle&amp;publication_year=1988&amp;journal=Br%20J%20Cancer&amp;volume=57&amp;pages=186-9">Google Scholar</a></div>
                        </div>
                        
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/89/7/488.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/89/7/506.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/89/7.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (1997) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    89
                                    </span><span class="slug-issue">
                                    (7):
                                    </span><span class="slug-pages">
                                    497-505.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/89.7.497" class="slug-doi">10.1093/jnci/89.7.497</span>
                                    </span>
                                 </cite>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/89/7/497.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/89/7/497.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=Articles&amp;sortspec=date&amp;submit=Submit">Article</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;89/7/497" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B89%2F7%2F497&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/89/7/497.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=89/7/497&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/89/7/497.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3B89.7.497&amp;citation=%2089%20%287%29:%20497&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B89%2F7%2F497&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=9086006&amp;link_type=MED_NBRS" class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B89%2F7%2F497">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B89%2F7%2F497">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Portal%20Vein%20Chemotherapy%20for%20Colorectal%20Cancer%3A%20a%20Meta-analysis%20of%204000%20Patients%20in%2010%20Studies%3A%20&amp;publicationDate=04%2F02%2F1997&amp;author=&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2F89.7.497&amp;volumeNum=89&amp;issueNum=7&amp;startPage=497&amp;endPage=505&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/89/7/497.full?cited-by=yes&amp;legid=jnci;89/7/497#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/89/7/497" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/89/7/497?access_num=/jnci/89/7/497" rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F89%2F7%2F497&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/89/7/497.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=9086006&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="/content/89/7/497.full?related-urls=yes&amp;legid=jnci;89/7/497#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B89%2F7%2F497&amp;current-view-path=/content/89/7/497.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/89/7/497&amp;title=Portal%20Vein%20Chemotherapy%20for%20Colorectal%20Cancer%3A%20a%20Meta-analysis%20of%204000%20Patients%20in%2010%20Studies+--+%2089%20%287%29%3A%20497+--+jnci&amp;doi=10.1093/jnci/89.7.497&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/89/7/497&amp;title=Portal%20Vein%20Chemotherapy%20for%20Colorectal%20Cancer%3A%20a%20Meta-analysis%20of%204000%20Patients%20in%2010%20Studies+--+%2089%20%287%29%3A%20497+--+jnci&amp;doi=10.1093/jnci/89.7.497&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/89/7/497&amp;title=Portal%20Vein%20Chemotherapy%20for%20Colorectal%20Cancer%3A%20a%20Meta-analysis%20of%204000%20Patients%20in%2010%20Studies+--+%2089%20%287%29%3A%20497+--+jnci&amp;doi=10.1093/jnci/89.7.497&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/89/7/497&amp;title=Portal%20Vein%20Chemotherapy%20for%20Colorectal%20Cancer%3A%20a%20Meta-analysis%20of%204000%20Patients%20in%2010%20Studies+--+%2089%20%287%29%3A%20497+--+jnci&amp;doi=10.1093/jnci/89.7.497&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/89/7/497&amp;title=Portal%20Vein%20Chemotherapy%20for%20Colorectal%20Cancer%3A%20a%20Meta-analysis%20of%204000%20Patients%20in%2010%20Studies+--+%2089%20%287%29%3A%20497+--+jnci&amp;doi=10.1093/jnci/89.7.497&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/89/7/497&amp;title=Portal%20Vein%20Chemotherapy%20for%20Colorectal%20Cancer%3A%20a%20Meta-analysis%20of%204000%20Patients%20in%2010%20Studies+--+%2089%20%287%29%3A%20497+--+jnci&amp;doi=10.1093/jnci/89.7.497&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-1">Materials and Methods</a></li>
                        <li><a href="#sec-2">Statistical Methods</a></li>
                        <li><a href="#sec-3">Results</a></li>
                        <li><a href="#sec-7">Discussion</a></li>
                        <li><a href="#notes-1">Notes</a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/89/7/497.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/89/7/497.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>